Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256901 · ClinicalTrials.gov registry record · Phase 4
Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy
A Phase 4 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT05256901 is a Phase 4 study that was terminated before completion, run by Emory University. The registered enrollment target is 22 participants.
The verdict
NCT05256901, a Phase 4 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study is designed as a randomized controlled trial with patients assigned to neuromuscular reversal with either sugammadex or neostigmine/glycopyrrolate reversal. The study will not be blinded to the anesthesiologist to allow for appropriate decision-making on timing and dosage of reversal. This is a single-center study.
Interventions
- DRUG Sugammadex
- DRUG Neostigmine/Glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2024-08-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05256901
The ClinicalTrials.gov registry entry for NCT05256901 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT05256901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05256901 about?
NCT05256901 is a clinical study titled "Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy". This study is designed as a randomized controlled trial with patients assigned to neuromuscular reversal with either sugammadex or neostigmine/glycopyrrolate reversal. The study will not be blinded to the anesthesiologist to allow for appropriate decision-making on timing and dosage of reversal. Thi...
What is the current status of trial NCT05256901?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2023-07-19. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT05256901?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine/Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT05256901?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.